{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:19:33Z","timestamp":1790173173110,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ab.2019.113491","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T21:36:58Z","timestamp":1572557818000},"page":"113491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["VHH characterization.Recombinant VHHs: Production, characterization and affinity"],"prefix":"10.1016","volume":"589","author":[{"given":"Eric","family":"Chabrol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Stojko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Botzanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Fould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Antoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cianf\u00e9rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ab.2019.113491_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal antibodies","volume":"13","author":"Singh","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.ab.2019.113491_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/d41573-019-00014-x","article-title":"FDA drug approvals","volume":"18","author":"Mullard","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ab.2019.113491_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/17425247.2016.1124854","article-title":"Antibody-mediated delivery of therapeutics for cancer therapy","volume":"13","author":"Parakh","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ab.2019.113491_bib4","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1038\/s41598-018-35869-4","article-title":"Engineering of a GLP-1 analogue peptide\/anti-PCSK9 antibody fusion for type 2 diabetes treatment","volume":"8","author":"Chodorge","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ab.2019.113491_bib5","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1038\/s41467-018-06086-4","article-title":"In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies","volume":"9","author":"Laustsen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ab.2019.113491_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ab.2019.113491_bib7","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40265-016-0673-1","article-title":"Bezlotoxumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ab.2019.113491_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ab.2019.113491_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jprot.2014.02.034","article-title":"From target discovery to clinical trials with armed antibody products","volume":"107","author":"Elia","year":"2014","journal-title":"J Proteomics"},{"key":"10.1016\/j.ab.2019.113491_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ab.2019.113491_bib11","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ab.2019.113491_bib12","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, Trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ab.2019.113491_bib13","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1172\/JCI120481","article-title":"Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release","volume":"128","author":"Szot","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ab.2019.113491_bib14","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/1535-7163.MCT-17-0982","article-title":"Antitumor activity of MEDI3726 (ADCT-401), a pyrrolobenzodiazepine antibody-drug conjugate targeting PSMA, in preclinical models of prostate cancer","volume":"17","author":"Cho","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ab.2019.113491_bib15","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1535-7163.MCT-16-0431","article-title":"RN927C, a site-specific trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models","volume":"15","author":"Strop","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ab.2019.113491_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/pr.114.009373","article-title":"Antibody drug conjugates for cancer therapy","volume":"68","author":"Polakis","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ab.2019.113491_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13238-017-0433-3","article-title":"Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy","volume":"9","author":"Mimura","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.ab.2019.113491_bib18","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1073\/pnas.1711720115","article-title":"Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region","volume":"115","author":"van de Bovenkamp","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ab.2019.113491_bib19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acs.analchem.7b03965","article-title":"Dual data-independent acquisition approach combining global HCP profiling and absolute quantification of key impurities during bioprocess development","volume":"90","author":"Husson","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ab.2019.113491_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.copbio.2007.04.010","article-title":"Alternative non-antibody scaffolds for molecular recognition","volume":"18","author":"Skerra","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ab.2019.113491_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3389\/fimmu.2017.00865","article-title":"Enhancing stability of camelid and shark single domain antibodies: an overview","volume":"8","author":"Goldman","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ab.2019.113491_bib22","series-title":"Single Domain Antibodies","first-page":"15","article-title":"Introduction to heavy chain antibodies and derived nanobodies","author":"Vincke","year":"2012"},{"key":"10.1016\/j.ab.2019.113491_bib23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ab.2019.113491_bib24","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody\u2013drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ab.2019.113491_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1535-7163.MCT-17-0710","article-title":"Characterization of ABBV-221, a tumor-selective EGFR-targeting antibody drug conjugate","volume":"17","author":"Phillips","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ab.2019.113491_bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-17-0697","article-title":"Intratumoral payload concentration correlates with the activity of antibody\u2013drug conjugates","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ab.2019.113491_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/1535-7163.MCT-17-0354","article-title":"IMMU-140, a novel SN-38 antibody\u2013drug conjugate targeting HLA-DR, mediates dual cytotoxic effects in hematologic cancers and malignant melanoma","volume":"17","author":"Cardillo","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ab.2019.113491_bib28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1158\/1535-7163.MCT-17-0813","article-title":"An anti-GDNF family receptor alpha 1 (GFRA1) antibody\u2013drug conjugate for the treatment of hormone receptor\u2013positive breast cancer","volume":"17","author":"Bhakta","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ab.2019.113491_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2007.04.005","article-title":"Improved anti-IgG and HSA affinity ligands: clinical application of VHH antibody technology","volume":"324","author":"Klooster","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ab.2019.113491_bib30","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00259-013-2471-2","article-title":"Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery","volume":"40","author":"Kijanka","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ab.2019.113491_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13550-016-0166-y","article-title":"Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization","volume":"6","author":"Kijanka","year":"2016","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ab.2019.113491_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsb.2017.05.008","article-title":"A novel immuno-gold labeling protocol for nanobody-based detection of HER2 in breast cancer cells using immuno-electron microscopy","volume":"199","author":"Kijanka","year":"2017","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.ab.2019.113491_bib33","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1080\/19420862.2017.1342914","article-title":"Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease","volume":"9","author":"Vandesquille","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ab.2019.113491_bib34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/pro.3601","article-title":"General lack of structural characterization of chemically synthesized long peptides","volume":"28","author":"Boutin","year":"2019","journal-title":"Protein Sci."},{"key":"10.1016\/j.ab.2019.113491_bib35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.biotechadv.2011.05.006","article-title":"Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics","volume":"30","author":"Kaltashov","year":"2012","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ab.2019.113491_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2015.03.012","article-title":"Getting to the core of protein pharmaceuticals\u2014comprehensive structure analysis by mass spectrometry","volume":"93","author":"Leurs","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ab.2019.113491_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jssc.201700988","article-title":"Advances in native high-performance liquid chromatography and intact mass spectrometry for the characterization of biopharmaceutical products","volume":"41","author":"Tassi","year":"2018","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.ab.2019.113491_bib38","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ab.2019.113491_bib39","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.3389\/fimmu.2018.02559","article-title":"Perspectives for the development of CD38-specific heavy chain antibodies as therapeutics for multiple myeloma","volume":"9","author":"Bannas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ab.2019.113491_bib40","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1021\/ac1022953","article-title":"Collision cross sections of proteins and their complexes: a calibration framework and database for gas-phase structural biology","volume":"82","author":"Bush","year":"2010","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ab.2019.113491_bib41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mas.21585","article-title":"Recommendations for reporting ion mobility Mass Spectrometry measurements","volume":"38","author":"Gabelica","year":"2019","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.ab.2019.113491_bib42","doi-asserted-by":"crossref","first-page":"11516","DOI":"10.1021\/acs.analchem.5b03292","article-title":"CIUSuite","volume":"87","author":"Eschweiler","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ab.2019.113491_bib43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/1475-2859-11-56","article-title":"SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm","volume":"11","author":"Lobstein","year":"2012","journal-title":"Microb. Cell Factories"},{"key":"10.1016\/j.ab.2019.113491_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pep.2017.02.007","article-title":"Enhanced expression and purification of camelid single domain VHH antibodies from classical inclusion bodies","volume":"136","author":"Maggi","year":"2017","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ab.2019.113491_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pep.2016.11.005","article-title":"High-level expression and efficient refolding of therapeutically important recombinant human Interleukin-3 (hIL-3) in E. coli","volume":"131","author":"Dagar","year":"2017","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ab.2019.113491_bib46","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/bp0498793","article-title":"Role of arginine in protein refolding, solubilization, and purification","volume":"20","author":"Tsumoto","year":"2004","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ab.2019.113491_bib47","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/ijc.26145","article-title":"A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth","volume":"129","author":"Roovers","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ab.2019.113491_bib48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/305831a0","article-title":"Sensitivity of circular dichroism to protein tertiary structure class","volume":"305","author":"Manavalan","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.ab.2019.113491_bib49","doi-asserted-by":"crossref","first-page":"W315","DOI":"10.1093\/nar\/gky497","volume":"46","author":"Micsonai","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ab.2019.113491_bib50","doi-asserted-by":"crossref","first-page":"E3095","DOI":"10.1073\/pnas.1500851112","article-title":"Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy","volume":"112","author":"Micsonai","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ab.2019.113491_bib51","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.str.2013.05.008","article-title":"Structural evaluation of EGFR inhibition mechanisms for nanobodies\/VHH domains","volume":"21","author":"Schmitz","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.ab.2019.113491_bib52","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s13361-012-0393-z","article-title":"Do charge state signatures guarantee protein conformations?","volume":"23","author":"Hall","year":"2012","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ab.2019.113491_bib53","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jasms.2008.05.018","article-title":"Do ionic charges in ESI MS provide useful information on macromolecular structure?","volume":"19","author":"Kaltashov","year":"2008","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ab.2019.113491_bib54","article-title":"Native mass spectrometry as a tool in structural biology","volume":"17","author":"Lorenzen","year":"2010","journal-title":"Curr Protoc Protein Sci Chapter"},{"key":"10.1016\/j.ab.2019.113491_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13361-016-1490-1","article-title":"Are charge-state distributions a reliable tool describing molecular ensembles of intrinsically disordered proteins by native MS?","volume":"28","author":"Natalello","year":"2017","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ab.2019.113491_bib56","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/17460441.2017.1363734","article-title":"An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery","volume":"12","author":"Masson","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ab.2019.113491_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.aca.2012.01.037","article-title":"Probing protein interactions with hydrogen\/deuterium exchange and mass spectrometry-a review","volume":"721","author":"Percy","year":"2012","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.ab.2019.113491_bib58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/epr.10.109","article-title":"Differential hydrogen\/deuterium exchange mass spectrometry analysis of protein-ligand interactions","volume":"8","author":"Chalmers","year":"2011","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.ab.2019.113491_bib59","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/19420862.2017.1380762","article-title":"Epitope characterization of anti-JAM-A antibodies using orthogonal mass spectrometry and surface plasmon resonance approaches","volume":"9","author":"Terral","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ab.2019.113491_bib60","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s13361-015-1083-4","article-title":"Effective application of bicelles for conformational analysis of G protein-coupled receptors by hydrogen\/deuterium exchange mass spectrometry","volume":"26","author":"Duc","year":"2015","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ab.2019.113491_bib61","doi-asserted-by":"crossref","first-page":"14223","DOI":"10.1038\/srep14223","article-title":"Structural models of intrinsically disordered and calcium-bound folded states of a protein adapted for secretion","volume":"5","author":"O'Brien","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ab.2019.113491_bib62","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.str.2017.07.003","article-title":"KRAS G12C drug development: discrimination between switch II pocket configurations using hydrogen\/deuterium-exchange mass spectrometry","volume":"25","author":"Lu","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.ab.2019.113491_bib63","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/cb400619v","article-title":"Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen\/deuterium exchange mass spectrometry","volume":"9","author":"Trelle","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ab.2019.113491_bib64","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/rcm.1290050415","article-title":"Conformational changes in proteins probed by hydrogen-exchange electrospray-ionization mass spectrometry","volume":"5","author":"Katta","year":"1991","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ab.2019.113491_bib65","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s13361-016-1350-z","article-title":"Real-time HD exchange kinetics of proteins from buffered aqueous solution with electrothermal supercharging and top-down tandem mass spectrometry","volume":"27","author":"Going","year":"2016","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ab.2019.113491_bib66","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jasms.2005.02.020","article-title":"Transient structural disorder as a facilitator of protein-ligand binding: native H\/D exchange-mass spectrometry study of cellular retinoic acid binding protein I","volume":"16","author":"Xiao","year":"2005","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ab.2019.113491_bib67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nchem.1889","article-title":"The power of ion mobility-mass spectrometry for structural characterization and the study of conformational dynamics","volume":"6","author":"Lanucara","year":"2014","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ab.2019.113491_bib68","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1039\/B914002F","article-title":"Ion mobility mass spectrometry of proteins and protein assemblies","volume":"39","author":"Uetrecht","year":"2010","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ab.2019.113491_bib69","doi-asserted-by":"crossref","first-page":"14173","DOI":"10.1002\/anie.201606029","article-title":"Retention of native protein structures in the absence of solvent: a coupled ion mobility and spectroscopic study","volume":"55","author":"Seo","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ab.2019.113491_bib70","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1021\/ac902784n","article-title":"Combination of noncovalent mass spectrometry and traveling wave ion mobility spectrometry reveals sugar-induced conformational changes of central glycolytic genes repressor\/DNA complex","volume":"82","author":"Atmanene","year":"2010","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ab.2019.113491_bib71","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1021\/ac203223h","article-title":"Exploring key parameters to detect subtle ligand-induced protein conformational changes using traveling wave ion mobility mass spectrometry","volume":"84","author":"Atmanene","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ab.2019.113491_bib72","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1039\/C5AN01311A","article-title":"Ion mobility coupled to native mass spectrometry as a relevant tool to investigate extremely small ligand-induced conformational changes","volume":"140","author":"Stojko","year":"2015","journal-title":"Analyst"},{"key":"10.1016\/j.ab.2019.113491_bib73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cbpa.2017.11.010","article-title":"Collision induced unfolding of isolated proteins in the gas phase: past, present, and future","volume":"42","author":"Dixit","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ab.2019.113491_bib74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijms.2017.12.002","article-title":"Collision induced unfolding and dissociation differentiates ATP-competitive from allosteric protein tyrosine kinase inhibitors","volume":"427","author":"Rabuck-Gibbons","year":"2018","journal-title":"Int. J. Mass Spectrom."},{"key":"10.1016\/j.ab.2019.113491_bib75","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/19420862.2017.1316914","article-title":"Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates","volume":"9","author":"Botzanowski","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ab.2019.113491_bib76","doi-asserted-by":"crossref","first-page":"8865","DOI":"10.1021\/acs.analchem.8b00912","article-title":"Native mass spectrometry, ion mobility, and collision-induced unfolding for conformational characterization of IgG4 monoclonal antibodies","volume":"90","author":"Hernandez-Alba","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ab.2019.113491_bib77","first-page":"1212","article-title":"The development of nanobodies for therapeutic applications","volume":"10","author":"van Bockstaele","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ab.2019.113491_bib78","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/1078-0432.CCR-17-3795","article-title":"Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors","volume":"24","author":"Abrams","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ab.2019.113491_bib79","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1158\/1535-7163.MCT-16-0393","article-title":"Development of a novel antibody-drug conjugate for the potential treatment of ovarian, lung, and renal cell carcinoma expressing TIM-1","volume":"15","author":"Thomas","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ab.2019.113491_bib80","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-15-2474","article-title":"Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies","volume":"22","author":"Almhanna","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ab.2019.113491_bib81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ab.2016.12.014","article-title":"Screening ubiquitin specific protease activities using chemically synthesized ubiquitin and ubiquitinated peptides","volume":"519","author":"Bacchi","year":"2017","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ab.2019.113491_bib82","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/pro.3051","article-title":"Total chemical synthesis, refolding, and crystallographic structure of fully active immunophilin calstabin 2 (FKBP12.6)","volume":"25","author":"Bacchi","year":"2016","journal-title":"Protein Sci."},{"key":"10.1016\/j.ab.2019.113491_bib83","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/pro.3712","article-title":"VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH","volume":"28","author":"Hartmann","year":"2019","journal-title":"Protein Sci."},{"key":"10.1016\/j.ab.2019.113491_bib84","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/mab.2016.0003","article-title":"Characterization and selection of 3-(1-Naphthoyl)-indole derivative-specific alpaca VHH antibodies using a phage display library","volume":"35","author":"Nakayama","year":"2016","journal-title":"Monoclon. Antibodies Immunodiagn. Immunother."},{"key":"10.1016\/j.ab.2019.113491_bib85","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.molimm.2018.11.016","article-title":"Selection and characterization of protective anti-chikungunya virus single domain antibodies","volume":"105","author":"Liu","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ab.2019.113491_bib86","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s13104-018-3955-8","article-title":"Isolation and characterization of camelid single-domain antibodies against HER2","volume":"11","author":"Hussack","year":"2018","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ab.2019.113491_bib87","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejpb.2018.11.014","article-title":"Sortagging of liposomes with a murine CD11b-specific VHH increases in vitro and in vivo targeting specificity of myeloid cells","volume":"134","author":"W\u00f6ll","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ab.2019.113491_bib88","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/bab.1654","article-title":"Development and characterization of a camelid single-domain antibody directed to human CD22 biomarker","volume":"65","author":"Faraji","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.ab.2019.113491_bib89","doi-asserted-by":"crossref","first-page":"11452","DOI":"10.1074\/jbc.M116.774141","article-title":"Identification and characterization of Nanobodies targeting the EphA4 receptor","volume":"292","author":"Schoonaert","year":"2017","journal-title":"J. Biol. Chem."}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269719307821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269719307821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T21:27:28Z","timestamp":1757712448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269719307821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":89,"alternative-id":["S0003269719307821"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2019.113491","relation":{},"ISSN":["0003-2697"],"issn-type":[{"value":"0003-2697","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VHH characterization.Recombinant VHHs: Production, characterization and affinity","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2019.113491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113491"}}